Protein geranylgeranyltransferase type I (
GGTase-I) is responsible for the posttranslational lipidation of CAAX
proteins such as RHOA, RAC1, and cell division cycle 42 (CDC42). Inhibition of
GGTase-I has been suggested as a strategy to treat
cancer and a host of other diseases. Although several
GGTase-I inhibitors (GGTIs) have been synthesized, they have very different properties, and the effects of GGTIs and
GGTase-I deficiency are unclear. One concern is that inhibiting
GGTase-I might lead to severe toxicity. In this study, we determined the effects of
GGTase-I deficiency on cell viability and K-RAS-induced
cancer development in mice. Inactivating the gene for the critical beta subunit of
GGTase-I eliminated
GGTase-I activity, disrupted the actin cytoskeleton, reduced cell migration, and blocked the proliferation of fibroblasts expressing oncogenic K-RAS. Moreover, the absence of
GGTase-I activity reduced lung
tumor formation, eliminated myeloproliferative phenotypes, and increased survival of mice in which expression of oncogenic K-RAS was switched on in lung cells and myeloid cells. Interestingly, several cell types remained viable in the absence of
GGTase-I, and myelopoiesis appeared to function normally. These findings suggest that inhibiting
GGTase-I may be a useful strategy to treat K-RAS-induced
malignancies.